Health Kick Podcast: Deep dive into AdAlta’s East to West strategy

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim chats with AdAlta (ASX:1AD) CEO and managing director Dr Tim Oldham.

For several years, AdAlta has been laser focused on its lead asset AD-214, an innovative first in class product for treating fibrotic diseases.

After taking the asset as far as it could alone, and recognising the need to be agile within the life sciences and biotech sectors, the company has shifted its focus to bringing a pipeline of clinical stage assets into fruition.

It’s East to West strategy focuses on bringing Asian cellular immunotherapies to Western markets.

In this episode, Oldham explains the shift, how the strategy works and what the company has been up to. Tune in to hear all about it.

This podcast was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.